INTRODUCTION
Rabies virus (RABV) is the type species of the lyssavirus genus in the rhabdoviridae family. Its small, negative-stranded RNA genome encodes only five true genes (1, 2) . Although relatively simple, this zoonotic virus has a devastating impact worldwide. The majority of human rabies deaths occur in 4 children in the developing world, and it is estimated that at least 55 000 humans die of rabies each year in Africa and Asia alone (3) .
Although RABV infection historically has been viewed as a death sentence once the virus reaches the brain, there is a small but growing number of humans who survived rabies even though the virus entered the brain (4, 5) . Due to such cases and to research using animal models of RABV infection (6) (7) (8) , many believe that the immune system may be capable of clearing RABV from the brain without causing irreparable immunopathology. It is clear, however, that therapeutic intervention will be necessary in the vast majority of cases. Some theoretical or experimental rabies treatments involve slowing virus replication and/or spread by: induction of hypothermia (9) ; the highly controversial use of therapeutic coma (5); enhancing immune cell entry into the CNS (10); superinfection with an attenuated RABV (11, 12) ; and systemic or intrathecal administration of anti-viral drugs and interferons (IFN) (13) . For decades while many researchers have been studying the effects of type I IFN (predominantly IFN and ) during RABV infection our work has focused primarily on the role(s) of IFN during RABV clearance from the CNS.
IFN is a pleiotropic cytokine and is the only known form of type II interferon.
Although originally discovered by its ability to "interfere" with virus infection (14) , its immunomodulatory functions were quickly recognized, and it is now widely accepted that IFN has many important functions in both innate and adaptive immunity. Some of these include: upregulation of adhesion molecules; activation of macrophages and NK cells; T cell activation and differentiation; upregulation of MHC molecules; antibody isotype switching; as well as induction of reactive oxygen species and reactive nitrogen intermediates (15) . These are merely a sample of what IFN induces as it is known to affect the expression of hundreds of genes (16) . Additionally, cross-talk between type I and type II IFN has been shown (17) , suggesting IFN can amplify its anti-viral effects via the induction of type I IFN. Furthermore, it is known that IFN can potentiate the action of type I IFN (18) and act synergistically with them (19) . Since its discovery, researchers and clinicians have been trying to harness IFN for its potential therapeutic effects. It has been tested experimentally as an adjuvant in vaccines (20, 21) and as treatment in animal models of disease such as tuberculosis (22) , each with varying degrees of success. Currently the only FDA-approved uses for IFN in humans are treatments for chronic granulomatous disease (23) and osteopetrosis (24), but IFN is also prescribed by veterinarians to treat canine atopic dermatitis (25) . These clinical uses of IFN highlight its pleiotropic nature as the mechanisms of action in these diseases are through enhanced innate immunity, activation of osteoclasts and suppression of the adaptive immune response, respectively.
Our previous work has shown that IFN mRNA expression in the brains of mice infected with attenuated RABV strongly correlates with blood-brain barrier (BBB) permeability changes and clearance of RABV from the CNS (6, 26) . Recent 6 experiments confirm the importance of IFN during RABV clearance from the CNS, supporting the concept that IFN is at the center of the signaling pathway that alters tight junction protein expression and leads to increased BBB permeability and survival from RABV infection (27) . These rabies-specific data, as well as the more commonly known roles of IFN in the innate and adaptive arms of the immune response, suggest that therapeutically enhancing IFN expression in the CNS during a rabies infection may prevent virus spread and aid the clearance of RABV from CNS tissues through a number of mechanisms.
Therefore, to more precisely determine the effects of IFN expression in the CNS on pathogenic RABV infection, we engineered a pathogenic RABV to express the murine IFN gene. We report that RABV-expressed IFN highly attenuates a pathogenic RABV in mice, and that this attenuation is due, at least in part, to upregulation of type I IFN.
MATERIALS AND METHODS:
Mice. Female Swiss Webster mice were purchased from Taconic Farms (Germantown, NY). Female C57Bl/6J mice and IFN -/-mice on a C57Bl/6 background were purchased from Jackson Laboratories (Bar Harbor, ME).
WT129 and IFNAR -/-mice were from investigator breeding colonies maintained at Thomas Jefferson University and were originally provided by Michel Aguet (28).
All mouse experiments were approved by the Thomas Jefferson University
Institutional Animal Care and Use Committee. Viruses. SPBN, the prototype recombinant RABV was derived from the SADB19 strain (30, 31) . Although SPBN is often referred to as a vaccine vector, when administered to mice intranasally (i.n.), it is highly pathogenic. The wild type RABV strain DRV4 was isolated from a human rabies victim and propagated in NA cells as previously described (32) .
Construction of recombinant viruses.
The recombinant RABVs, SPBN(-) and SPBN, were engineered as described previously (33 and absorbance at 450 nm was recorded.
Quantitative PCR. RNA tot was extracted from brain samples using a Qiagen
RNeasy kit (Qiagen, Valencia, CA) and modified Qiagen protocol previously described (6) . Briefly, tissues were homogenized by aspirating through a sterile, 20 gauge needle approximately 15 times in TriReagent (MRC, Cincinnati, OH).
Homogenized samples were spun in a Heraeus Biofuge pico benchtop centrifuge (Thermo Scientific, Langenselbold, Germany) at 12 000 rpm for 15 min at RT.
The aqueous layer was removed and mixed with an equal portion of 70% ethanol and then added to the Qiagen spin column. All subsequent steps are outlined in the Qiagen manual, including the optional on-column DNAse I digestion which was used. After RNA tot extraction, cDNA was prepared using oligo dT 15 for Potency (34) .
RESULTS

Recombinant rabies virus expresses murine IFN. Recombinant RABVs were
constructed using the pathogenic SPBN backbone vector. Fig. 1A shows a wildtype RABV genome while 1C depicts the IFN-expressing SPBN, termed SPBN.
To control for any changes in replication efficiency that might occur due to increased size of the RABV genome, we used the previously constructed SPBN(-) ( Both viruses grow to relatively high titers (>10 7 ffu/ml). In AS cells there is a similar result with less than one log 10 difference in growth by 48 hours p.i. in the single-step growth curve (Fig. 3B) . IFN production may slow the spread of SPBN in AS cells, however, as there is greater than one log 10 difference between the virus titers at 72 hours p.i. (Fig. 3E) . In contrast to the minor differences seen in NA and AS cell lines, the replication rate and spread of SPBN in MC cells is several logs 10 lower as compared to SPBN(-) (Fig. 3C, 3F ).
The antiviral mechanisms in the MC cells appear to be very rapidly activated, as this multi-log difference in replication is evident as early as 24 hours p.i. This significant decrease in SPBN replication as compared to SPBN(-) indicates that the IFN produced by SPBN and measured by ELISA (Fig. 2D) infection from 6 to 48 hours p.i. (Fig. 9B ). This effect is also seen when measuring IFN induction (Fig. 9C) To determine if SPBN also induces higher levels of type I IFN in the brain than SPBN(-), we infected groups of C57BL/6 mice with either virus. We sacrificed the mice at early timepoints during infection and analyzed the samples by qPCR for the presence of viral RNA as well as type I and type II IFN mRNA. It is widely held that IFN expression levels increase as virus replication increases (39) . In fact, mice dying from RABV and other related viruses, often have highest levels of circulating IFN just before death (40) . Therefore, we compared IFN expression levels to the amount of virus replication in the olfactory bulb (OB) (Fig. 10A,D,G) , cerebellum (CB) (Fig. 10B ,E,H) and cerebral cortex (CX) (Fig.   10C,F,I ) of infected mice. After normalizing the IFN message levels to RABV N mRNA, it is clear that SPBN induces significantly higher levels of IFN (Fig. 10A-C ) and type I IFN (Fig. 10D-I (Fig. 10C) , as compared to SPBN(-)-infected tissues.
DISCUSSION.
IFN is a pleiotropic cytokine capable of modulating both the innate and adaptive immune responses and, as hypothesized, the addition of murine IFN to the genome of SPBN highly attenuated the pathogenicity of this virus in mice. To determine which IFN-inducible antiviral mechanism(s) led to the strong attenuation of the RABV, we infected cell lines relevant to RABV infection as well as wild-type mice and knock-out mice with specific immune deficits. Together the data support the concept that IFN production by SPBN attenuates the virus by enhancing the production of type I IFNs early in the infection. Thus IFN, an important product of adaptive immunity, inhibits RABV replication by activating well-established innate antiviral mechanisms.
We previously showed a significant correlation exists among IFN expression, BBB permeability and RABV clearance from the CNS (6, 26) . The changes in BBB permeability are necessary to allow immune effectors to enter the CNS and eliminate the RABV infection. Various studies suggest that the mechanism involves IFN-mediated induction of radicals (26, 41) , which culminates in the alteration of tight-junction proteins (27) . In the present study, however, we did not observe an increase in BBB permeability due to IFN overexpression. While 
